Sahpra's Glp-1 Crackdown Exposes A Trust Crisis In South Africa's Longevity Industry
As regulators move against unregistered GLP-1 and GIP medicines, NADclinic South Africa says the next phase of longevity medicine must be built on clinical governance, diagnostics, transparency and responsible access.
South Africans have never been more interested in longevity, preventative health and human performance.
Search interest and consumer conversations